Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-cand-3_18-cv-00355/USCOURTS-cand-3_18-cv-00355-3/pdf.json

Nature of Suit Code: 890
Nature of Suit: Other Statutory Actions
Cause of Action: 15:1125 Trademark Infringement (Lanham Act)

---

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

PETER M. BRODY (pro hac vice)

MARK S. POPOFSKY(CSB # 175476)

ROPES & GRAY LLP

2099 Pennsylvania Avenue, NW

Washington, DC 20006-6807

Tel: 202-508-4600

Fax: 202-508-4650

peter.brody@ropesgray.com

DAVID S. CHUN (CSB # 315958)

ROPES & GRAY LLP

1900 University Avenue

East Palo Alto, CA 94303-2284

Tel: 650-617-4000

Fax: 650-617-4090

david.chun@ropesgray.com

ANNE JOHNSON PALMER (CSB # 

302235)

ROPES & GRAY LLP

Three Embarcadero Center

San Francisco, CA 94111-4006

Tel: 415-315-6300

Fax: 415-315-6350

anne.johnsonpalmer@ropesgray.com

Attorneys for Plaintiff,

BAUSCH HEALTH US, LLC

JOSEPH E. CWIK (pro hac vice)

UPADHYE CWIK LLP

135 S LaSalle St. Suite 1930

Chicago, IL 60603

Tel: 312.598.2610

joe@ipfdalaw.com

BENJAMIN L. ENGLAND (pro hac vice)

JESSICA R. RIFKIN (pro hac vice)

BENJAMIN L. ENGLAND & 

ASSOCIATES, LLC

810 Landmark Drive, Suite 126

Glen Burnie, MD 21061

Tel: (410) 220-2800

Fax: (443) 583-1464

blengland@fdaimports.com

jrrifkin@fdaimports.com

Attorneys for Defendant,

ECI PHARMACEUTICALS LLC

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

SAN FRANCISCO DIVISION

BAUSCH HEALTH US, LLC,

Plaintiff,

v.

ECI PHARMACEUTICALS LLC,

Defendant.

Case No. 18-CV-00355-RS

STIPULATION AND [PROPOSED] 

ORDER CONCERNING MODIFICATION 

OF SCHEDULING ORDER

Case 3:18-cv-00355-RS Document 155 Filed 01/23/20 Page 1 of 6
2

STIPULATION AND [PROPOSED] ORDER

CASE NO. 18-CV-00355-RS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Pursuant to Civil Local Rule 6-2, 7-1(a)(5), and 7-12, Defendant ECI Pharmaceuticals 

LLC (“ECI”) and Plaintiff Bausch Health US, LLC (“Bausch”) (jointly, the “Parties”), by and 

through their respective counsel, hereby stipulate as follows:

WHEREAS the following time modifications have been previously made in this case:

A thirty (30) day extension of time, until January 19, 2018, for Defendant to file a Rule 12 

motion, answer, or otherwise respond to the complaint in Plaintiff’s originally-filed action against 

Defendant and other parties (Dkt. 21; Chun Declaration in Support of Stipulation and Proposed 

Order (“Chun Decl.”), ¶ 5); 

A further extension of Defendant’s deadline to file a responsive pleading until twenty-one 

(21) days after Plaintiff filed its amended complaint in this severed action, which was so Ordered 

by the Court on January 16, 2018 (Dkt. 34; Chun Decl. ¶ 6);

A further extension of time permitting Plaintiff an extension of time to file its Opposition 

to Defendant’s Rule 12 Motion filing and Defendant an extension of time to file its Reply to 

March 27, 2018 and April 24, 2018, respectively (Dkt. 40; Chun Decl. ¶ 9);

A stay of the case from May 4, 2018 to July 31, 2018 pursuant to 28 U.S.C. § 1659(a) 

pending the determination or termination of ITC Investigation No. 337-TA-1109, captioned “In 

the Matter of Certain Clidinium Bromide and Products Containing Same” (Dkts. 70, 72; Chun 

Decl. ¶ 11);

A modification of the schedule setting the deadline for the Defendant to file its Reply in

Support of its Motion to Dismiss for October 12, 2018 and setting a Joint Hearing on the Motion 

to Dismiss for October 25, 2018 (Dkt. 79; Chun Decl. ¶ 12);

A modification of the schedule setting the deadline for Plaintiff to answer Defendant’s 

counterclaims and further modify the scheduling order (Dkt. 102) with respect to fact and expert 

discovery deadlines (Dkt. 136);

WHEREAS the Parties submitted to this Court under seal on January 9, 2020 a Joint 

Letter Brief Regarding Certain Discovery Disputes (“Joint Letter”);

WHEREAS the discovery disputes raised in the Parties’ Joint Letter were referred to 

Magistrate Judge Kandis A. Westmore on January 15, 2020 and remain pending;

Case 3:18-cv-00355-RS Document 155 Filed 01/23/20 Page 2 of 6
3

STIPULATION AND [PROPOSED] ORDER

CASE NO. 18-CV-00355-RS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

WHEREAS Defendant has indicated it intends to amend its pleadings on or before 

February 7, 2020, pursuant to the Court’s Further Case Management Scheduling Order (Dkt. 

150);

WHEREAS the Parties are engaged in active settlement discussions;

WHEREAS the Parties further agree to modify the current scheduling order (Dkt. 102, as 

modified by Order Dkt. 136) as follows:

Event Current Date Proposed Date

Close of all non-expert 

discovery

January 31, 2020 February 28, 2020

Designation of experts in 

accordance with FRCP 26(a)(2)

February 14, 2020 March 13, 2020

Designation of supplemental 

and rebuttal experts in 

accordance with FRCP 26(a)(2)

March 27, 2020 April 17, 2020

Completion of all discovery of 

expert witnesses pursuant FRCP 

26(b)(4)

May 8, 2020 No Change

Further Case Management 

Conference

January 16, 2020 at 10:00am No Change

Deadline for hearing of all 

pretrial motions

July 2, 2020 No Change

Pretrial Conference On or about September 2, 2020 

at 10:00am

No Change

Jury Trial Commences Beginning on or after 

September 28, 2020 at 9:00 am

No Change

WHEREAS the Parties believe that good cause exists for these extensions so that the 

parties can meet their discovery obligations, prepare for depositions, and continue settlement 

efforts, while leaving the existing trial date and remaining deadlines unaffected;

WHEREAS the Parties do not believe that these proposed time modifications would have 

any detrimental effect on the schedule for the case, or would cause prejudice to any party;

Case 3:18-cv-00355-RS Document 155 Filed 01/23/20 Page 3 of 6
4

STIPULATION AND [PROPOSED] ORDER

CASE NO. 18-CV-00355-RS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

NOW THERFORE, in order to effectuate the Parties’ intent as set forth herein, the Parties, 

by and through their respective counsel, stipulate to and respectfully request that the Court enter 

an Order to extend the discovery deadlines as shown above.

Dated: January 23, 2020 /s/ David S. Chun 

DAVID S. CHUN (CSB # 315958)

ROPES & GRAY LLP

1900 University Avenue

East Palo Alto, CA 94303-2284

Tel: 650-617-4000

Fax: 650-617-4090

david.chun@ropesgray.com

PETER M. BRODY (pro hac vice)

MARK S. POPOFSKY(CSB # 175476)

ROPES & GRAY LLP

2099 Pennsylvania Avenue, NW

Washington, DC 20006-6807

Tel: 202-508-4600

Fax: 202-508-4650

peter.brody@ropesgray.com

ANNE JOHNSON PALMER (CSB # 302235)

ROPES & GRAY LLP

Three Embarcadero Center

San Francisco, CA 94111-4006

Tel: 415-315-6300

Fax: 415-315-6350

anne.johnsonpalmer@ropesgray.com

Attorneys for Plaintiff,

BAUSCH HEALTH US, LLC

Dated: January 23, 2020 /s/ Joseph E. Cwik 

Joseph E. Cwik (pro hac vice)

UPADHYE CWIK LLP

135 S LaSalle St., Suite 1930

Chicago, IL 60603

Tel: 312.598.2610

joe@ipfdalaw.com

Case 3:18-cv-00355-RS Document 155 Filed 01/23/20 Page 4 of 6
5

STIPULATION AND [PROPOSED] ORDER

CASE NO. 18-CV-00355-RS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Benjamin L. England (pro hac vice)

Jessica R. Rifkin (pro hac vice)

BENJAMIN L. ENGLAND & ASSOCIATES, 

LLC

810 Landmark Drive, Suite 126

Glen Burnie, MD 21061

Tel: (410) 220-2800

Fax: (443) 583-1464

blengland@fdaimports.com

jrrifkin@fdaimports.com

Counsel for Defendant

ECI Pharmaceuticals, LLC

Case 3:18-cv-00355-RS Document 155 Filed 01/23/20 Page 5 of 6
6

STIPULATION AND [PROPOSED] ORDER

CASE NO. 18-CV-00355-RS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

[PROPOSED] ORDER

PURSUANT TO STIPULATION, IT IS SO ORDERED.

Dated: ______________, 2020. ___________________________________

Honorable Richard Seeborg

United States District Judge

1/23

Case 3:18-cv-00355-RS Document 155 Filed 01/23/20 Page 6 of 6